{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:03Z","timestamp":1790701743021,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109311","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:41:44Z","timestamp":1770565304000},"page":"109311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system"],"prefix":"10.1016","volume":"214","author":[{"given":"Xinmei","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109311_b0005","doi-asserted-by":"crossref","unstructured":"Z. Shannon S, N. Misako, Spotlight on Sotorasib (AMG 510) for KRAS (G12C) Positive Non-Small Cell Lung Cancer, Lung Cancer (Auckl) 12(0) (2021) 115-122.","DOI":"10.2147\/LCTT.S334623"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109311_b0010","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","article-title":"Targeting KRAS(G12C): from Inhibitory Mechanism to Modulation of Antitumor Effects in patients","volume":"183","author":"Dongsung","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109311_b0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/10600280231197459","article-title":"Targeted Therapies for previously \u201cUndruggable\u201d KRAS-Mutated Non-Small Cell Lung Cancer: a Review of Sotorasib and Adagrasib","volume":"58","author":"Mausey","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.lungcan.2026.109311_b0020","unstructured":"R. Gregory J, W. Douglas E, E. David S, A. Dara L, A. Wallace, B. Jessica R, B. Ankit, B. Debora S, C. Joe Y, C. Lucian R, D. Malcolm, D. Aakash P, D. Thomas J, D. Jonathan, D. Gregory A, G. Scott, G. Travis E, G. Matthew A, J. Aditya, L. Rudy P, L. Michael, L. Jules, L. Billy W, L. Christine M, M. Fabien, M. Erminia, M. Daniel, M. Trey C, N. Thomas, O. Dawn, O. Dwight H, P. Sandip P, P. Tejas, P. Patricio M, R. Jonathan, S. Theresa A, S. Aditi P, S. James, T. Alda, T. Tawee, Y. Jane, Y. Stephen C, Y. Edwin, G. Kristina M, H. Lisa, Non-Small Cell Lung Cancer, Version 4.2024, J Natl Compr Canc Netw 22(4) (2024) 249-274."},{"key":"10.1016\/j.lungcan.2026.109311_b0025","doi-asserted-by":"crossref","unstructured":"P. D, P. S, K. K, N. S, S. E F, F.-F. C, M. T S, R. M, V.S. P E, H. M D, P. S, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of oncology : official journal of the European Society for Medical Oncology 29(0) (2018) iv192-iv237.","DOI":"10.1093\/annonc\/mdy275"},{"key":"10.1016\/j.lungcan.2026.109311_b0030","unstructured":"P.S. Planchard D, Kerr K, et al, Clinical practice living guidelines: metastatic non-small-cell lung cancer, 2020. https:\/\/www. esmo.org\/. (Accessed 5.29 2024)."},{"key":"10.1016\/j.lungcan.2026.109311_b0035","unstructured":"N.I.f.H.a.C. Excellence, Sotorasib for previously treated KRAS G12C mutation-positive advanced nonsmall-cell lung cancer, 2022. https:\/\/www.nice.org.uk\/. (Accessed 5.29 2024)."},{"key":"10.1016\/j.lungcan.2026.109311_b0040","article-title":"Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal, Lung cancer (Amsterdam","volume":"191","author":"Ali","year":"2024","journal-title":"Netherlands)"},{"key":"10.1016\/j.lungcan.2026.109311_b0045","article-title":"Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. true, false or just another adverse effect of NSCLC treatment","volume":"37","author":"Paul","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109311_b0050","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver adverse events Associated with Sequential Anti-Programmed CellDeath (Ligand)1 and Sotorasib Therapy in KRAS(G12C)-Mutant Lung Cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109311_b0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2016.08.009","article-title":"Drug Hepatotoxicity: Newer Agents","volume":"21","author":"Bunchorntavakul","year":"2017","journal-title":"Clin. Liver Dis."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109311_b0060","first-page":"812","article-title":"KRAS-G12 inhibitors in lung cancer therapy: unveiling the toxicity profile through a pharmacovigilance study","volume":"32","author":"Li","year":"2024","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.lungcan.2026.109311_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107966","article-title":"Safety assessment of KRAS (G12C) inhibitors based on the FDA adverse Event Reporting System (FAERS) database: a real-world pharmacovigilance study","volume":"196","author":"Chen","year":"2024","journal-title":"Lung Cancer (amsterdam, Netherlands)"},{"key":"10.1016\/j.lungcan.2026.109311_b0070","article-title":"A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109311_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30437","article-title":"Post-marketing safety concerns of sotorasib: a disproportionality analysis based on FDA adverse event reporting system","volume":"10","author":"Ding","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.lungcan.2026.109311_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109311_b0085","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109311_b0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.lungcan.2026.109311_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109311_b0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109311_b0105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of Signal Detection Algorithms based on Frequency Statistical Model for Drug-Drug Interaction using Spontaneous Reporting Systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109311_b0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109311_b0115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109311_b0120","doi-asserted-by":"crossref","unstructured":"P. T, R. L R, J. B A, G. G J, Dysregulation of apoptosis as a mechanism of liver disease: an overview, Semin Liver Dis 18(2) (1998) 105-114.","DOI":"10.1055\/s-2007-1007147"},{"key":"10.1016\/j.lungcan.2026.109311_b0125","doi-asserted-by":"crossref","unstructured":"R. C M, F. G, M. X, K. B T, S. C J, A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation, J Clin Invest 101(12) (1998) 2790-2799.","DOI":"10.1172\/JCI1325"},{"key":"10.1016\/j.lungcan.2026.109311_b0130","doi-asserted-by":"crossref","unstructured":"S. S S, B. L N, K. A S, K. S A, D. N, A. H, S. E, D. K, C. S, L. V, T. M S, K. A F, N. A, P. J, B. A, M.-V. G, F. N B, G. R M, T. R J, A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis, Nat Genet 20(3) (1998) 233-238.","DOI":"10.1038\/3034"},{"key":"10.1016\/j.lungcan.2026.109311_b0135","doi-asserted-by":"crossref","unstructured":"L. J J, N. A L, Q. T, T. L C, E. S P, N. Y, C. R A, C. W E, B. C A, B. D A, H. B, The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy, Biochim Biophys Acta 1366(0) (1998) 177-196.","DOI":"10.1016\/S0005-2728(98)00112-1"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109311_b0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0168-8278(99)80360-2","article-title":"Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis","volume":"31","author":"Pessayre","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lungcan.2026.109311_b0145","doi-asserted-by":"crossref","unstructured":"M. M, S. S, H. H, H. E M, W. H, H. W J, S. W, K. P H, G. P R, Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1\/Fas) receptor\/ligand system and involves activation of wild-type p53, J Clin Invest 99(3) (1997) 403-413.","DOI":"10.1172\/JCI119174"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109311_b0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/jlb.61.6.647","article-title":"Mechanisms of neutrophil-induced parenchymal cell injury","volume":"61","author":"Jaeschke","year":"1997","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109311_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/taap.1996.0160","article-title":"Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils","volume":"139","author":"Jaeschke","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109311_b0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0300-483X(00)00437-6","article-title":"Role of macrophages and inflammatory mediators in chemically induced toxicity","volume":"160","author":"Laskin","year":"2001","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109311_b0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of Hepatotoxicity","volume":"65","author":"Hartmut","year":"2002","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109311_b0170","first-page":"303","article-title":"Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes, Hepatology (Baltimore","volume":"32","author":"Haouzi","year":"2000","journal-title":"Md.)"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109311_b0175","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-22-3655","article-title":"Facts and hopes on RAS Inhibitors and Cancer Immunotherapy","volume":"29","author":"Jesse","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109311_b0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from Immune Checkpoint Inhibitors: a Systematic Review and Management Recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.lungcan.2026.109311_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.648164","article-title":"Hepatotoxicity-Related adverse Effects of Proton Pump Inhibitors: a Cross-Sectional Study of Signal Mining and Analysis of the FDA adverse Event Report System Database","volume":"8","author":"Zeng","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.lungcan.2026.109311_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155411","article-title":"Emodin-8-O-\u03b2-D-glucopyranoside-induced hepatotoxicity and gender differences in zebrafish as revealed by integration of metabolomics and transcriptomics","volume":"128","author":"Han","year":"2024","journal-title":"Phytomedicine : International Journal of Phytotherapy and Phytopharmacology"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109311_b0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14737175.2017.1361322","article-title":"Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management","volume":"17","author":"Salem","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.lungcan.2026.109311_b0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jns.2017.11.019","article-title":"Clinical management of tardive dyskinesia: five steps to success","volume":"383","author":"Citrome","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.lungcan.2026.109311_b0205","unstructured":"J. Hartmut, G. Gregory J, C. Arthur I, H. Jack A, P. Dominique, L. John J, Mechanisms of hepatotoxicity, Toxicol Sci 65(2) (2002)."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109311_b0210","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109311_b0215","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and Outcomes of 899 patients with Drug-Induced Liver Injury: the DILIN prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109311_b0220","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00204-016-1918-1","article-title":"Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria","volume":"91","author":"Zhang","year":"2017","journal-title":"Arch. Toxicol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:48:09Z","timestamp":1790700489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"alternative-id":["S0169500226000553"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109311","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deep exploration of sotorasib-related hepatobiliary AEs: Based on FDA Adverse Event reporting system","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109311"}}